These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35616365)

  • 1. Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis.
    Mohapatra D; Gupta AK; Haldar P; Meena JP; Tanwar P; Seth R
    Pediatr Hematol Oncol; 2023 Feb; 40(1):86-97. PubMed ID: 35616365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.
    Donadieu J; Larabi IA; Tardieu M; Visser J; Hutter C; Sieni E; Kabbara N; Barkaoui M; Miron J; Chalard F; Milne P; Haroche J; Cohen F; Hélias-Rodzewicz Z; Simon N; Jehanne M; Kolenova A; Pagnier A; Aladjidi N; Schneider P; Plat G; Lutun A; Sonntagbauer A; Lehrnbecher T; Ferster A; Efremova V; Ahlmann M; Blanc L; Nicholson J; Lambilliote A; Boudiaf H; Lissat A; Svojgr K; Bernard F; Elitzur S; Golan M; Evseev D; Maschan M; Idbaih A; Slater O; Minkov M; Taly V; Collin M; Alvarez JC; Emile JF; Héritier S
    J Clin Oncol; 2019 Nov; 37(31):2857-2865. PubMed ID: 31513482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.
    Li Q
    J Dermatolog Treat; 2023 Dec; 34(1):2279901. PubMed ID: 37941458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
    Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
    Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous adverse events in children treated with vemurafenib for refractory BRAF
    Tardieu M; Néron A; Duvert-Lehembre S; Amine Larabi I; Barkaoui M; Emile JF; Seigneurin A; Boralevi F; Donadieu J
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29140. PubMed ID: 34109735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.
    Liu R; Guo Y; Han L; Feng S; Cao J; Sun Y; Cao Z; Cui X
    Clin Exp Med; 2023 Dec; 23(8):5269-5279. PubMed ID: 37572153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study.
    Lei J; Wang W; Lin D; Zhu C; Jia W; Weng W; Liu X; Ma Y; Wang Z; Yang L; He X; He Y; Li Y
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):12. PubMed ID: 38231288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
    Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
    Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective rescue treatment with vemurafenib of an infant with high-risk Langerhans cell histiocytosis.
    Gerbaux M; Diallo S; Dedeken L; Dangoisse C; Bott A; Heritier S; Salik D; Ferster A
    Ann Dermatol Venereol; 2020 Nov; 147(11):782-785. PubMed ID: 32653217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vemurafenib in refractory langerhans histiocytosis].
    Raciborska A; Małas Z; Tysarowski A
    Dev Period Med; 2018; 22(4):376-378. PubMed ID: 30636236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.
    Evseev D; Osipova D; Kalinina I; Raykina E; Ignatova A; Lyudovskikh E; Baidildina D; Popov A; Zhogov V; Semchenkova A; Litvin E; Kotskaya N; Cherniak E; Voronin K; Burtsev E; Bronin G; Vlasova I; Purbueva B; Fink O; Pristanskova E; Dzhukaeva I; Erega E; Novichkova G; Maschan A; Maschan M
    Blood Adv; 2023 Sep; 7(18):5246-5257. PubMed ID: 37216396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis.
    Eder SK; Schwentner R; Ben Soussia P; Abagnale G; Attarbaschi A; Minkov M; Halbritter F; Hutter C
    Blood Adv; 2022 Feb; 6(3):970-975. PubMed ID: 34619771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
    Abla O; Weitzman S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
    Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
    Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of BRAF-Inhibitor Therapy in BRAF
    Hazim AZ; Ruan GJ; Ravindran A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
    Oncologist; 2020 Dec; 25(12):1001-1004. PubMed ID: 32985015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor.
    Gandolfi L; Adamo S; Pileri A; Broccoli A; Argnani L; Zinzani PL
    J Natl Compr Canc Netw; 2015 Jun; 13(6):715-8. PubMed ID: 26085387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.
    Karri V; Lin H; Velazquez J; Batajoo A; Parekh D; Stanton W; Abhyankar H; El-Mallawany NK; Agrusa J; Eckstein O; Gulati N; Schwartz J; Woods-Swafford W; Boyd J; Saha A; Allen CE; McClain KL
    Br J Haematol; 2024 May; 204(5):1882-1887. PubMed ID: 38501390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.